What is your approach to long-term suppressive therapy of valganciclovir for a patient with a history of CMV anterior uveitis?

Once I confirm a diagnosis of CMV anterior uveitis (+ PCR), I treat patients with valganciclovir 900 mg PO twice daily for 21 days and then switch to prophylactic dosing of 900 mg daily for 6 months to 1 year. That being said, many patients have recurrences even on prophylactic dosing and need, in my experience, low-dose topical steroids. Unfortunately, this is based on common practice learned from mentors, as there are no randomized trials or specific guidelines for the treatment of CMV uveitis. It is important to mention that the dose needs to be renally adjusted and that one of the possible side effects is myelosuppression, so regular CBCs are needed.